`
`TRAVATAN Z Consumers and Patients Rebate
`
`http://www.travatanz.com/
`
`Go
`
`71 captures
`24 Jun 08 2 Jan 17
`
`DEC
`
`2008
`
`Select Text Size:
`
`Small
`Medium
`Large
`
`Rebate Home
`
`TRAVATAN Z® Solution Rebate Worksheet
`
`TRAVATAN Z® Solution Rebate Form
`
`CompleteProductInformation
`
`Save big on your
`TRAVATAN Z® Solution prescription.
`
`REBATE
`
`Restrictions Apply
`Complete your rebate form
`What would my rebate amount be?
`
`You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1
`800FDA1088.
`
`IMPORTANT SAFETY INFORMATION: TRAVATAN Z® solution is indicated for the reduction of elevated intraocular
`pressure (IOP) in patients with openangle glaucoma or ocular hypertension who are intolerant of other IOPlowering
`medications or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to
`another IOPlowering medication. TRAVATAN Z® solution is contraindicated in patients with known hypersensitivity to
`Exhibit 1028
`http://web.archive.org/web/20090401152511/http://www.travatanz.com/
`ARGENTUM
`
`1/2
`
`000001
`
`
`
`TRAVATAN Z Consumers and Patients Rebate
`2/24/2017
`travoprost or any other ingredients in this product. Prostaglandin analogues, including travoprost ophthalmic solution,
`DEC
`http://www.travatanz.com/
`Go
`0.004%, have been reported to cause changes to pigmented tissues. The most frequently reported changes have been
`71 captures
`increased pigmentation of the iris and periorbital tissue (eyelid) and increased pigmentation and growth of eyelashes.
`2008
`24 Jun 08 2 Jan 17
`These changes may be permanent. TRAVATAN Z® solution may gradually change eye color, increasing the amount of
`brown pigmentation in the iris by increasing the number of melanosomes (pigment granules) in melanocytes. The long term
`effects on the melanocytes and the consequences of potential injury to the melanocytes and/or deposition of pigment
`granules to other areas of the eye are currently unknown. The most common adverse event observed in studies with
`TRAVATAN® solution and TRAVATAN Z® solution was ocular hyperemia which was reported in 30 to 50 percent of
`patients. Ocular events reported at an incidence of 5 to 10 percent included decreased visual acuity, eye discomfort, foreign
`body sensation, pain and pruritus. The recommended dosage is one drop in the affected eye(s) once daily in the evening.
`Before using TRAVATAN Z® solution, please read the full prescribing information.
`
`Copyright © 2009 Alcon, Inc. a global company based in Hünenberg, Switzerland. The information and materials within
`this section pertain to the U.S. market only. Not all products are approved in every marked and approved labeling and
`instructions may vary by local country. See Privacy Policy and Terms & Conditions for the use of this site.
`
`Other Alcon brands: Systane.com ICAPSVitamins.com OptiFree.com Pataday.com Patanase.com Ciprodex.com
`AcrySofReSTOR.com
`
`http://web.archive.org/web/20090401152511/http://www.travatanz.com/
`
`2/2
`
`000002
`
`